Haemonetics Corporation

NYSE:HAE Stock Report

Market Cap: US$3.2b

Haemonetics Valuation

Is HAE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HAE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$142.42
Fair Value
58.3% undervalued intrinsic discount
10
Number of Analysts

Below Fair Value: HAE ($59.34) is trading below our estimate of fair value ($142.42)

Significantly Below Fair Value: HAE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HAE?

Key metric: As HAE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HAE. This is calculated by dividing HAE's market cap by their current earnings.
What is HAE's PE Ratio?
PE Ratio22.9x
EarningsUS$130.07m
Market CapUS$3.16b

Price to Earnings Ratio vs Peers

How does HAE's PE Ratio compare to its peers?

The above table shows the PE ratio for HAE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38.6x
MMSI Merit Medical Systems
53x13.6%US$6.4b
UFPT UFP Technologies
37x16.8%US$2.1b
STAA STAAR Surgical
49.7x33.9%US$1.1b
LNTH Lantheus Holdings
14.8x12.8%US$6.3b
HAE Haemonetics
22.9x21.3%US$3.2b

Price-To-Earnings vs Peers: HAE is good value based on its Price-To-Earnings Ratio (22.9x) compared to the peer average (39.1x).

Price to Earnings Ratio vs Industry

How does HAE's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
1.1xn/aUS$10.40m
PAVM PAVmed
0.5x-90.0%US$6.79m
UTRS Minerva Surgical
n/an/aUS$8.00
No more companies available in this PE range
HAE 22.9xIndustry Avg. 35.3xNo. of Companies8PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HAE is good value based on its Price-To-Earnings Ratio (22.9x) compared to the US Medical Equipment industry average (35.3x).

Price to Earnings Ratio vs Fair Ratio

What is HAE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HAE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.9x
Fair PE Ratio30.7x

Price-To-Earnings vs Fair Ratio: HAE is good value based on its Price-To-Earnings Ratio (22.9x) compared to the estimated Fair Price-To-Earnings Ratio (30.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HAE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$59.34
US$96.80
+63.1%
16.6%US$120.00US$68.00n/a10
Feb ’26US$69.05
US$110.80
+60.5%
10.5%US$125.00US$85.00n/a10
Jan ’26US$78.08
US$110.80
+41.9%
10.5%US$125.00US$85.00n/a10
Dec ’25US$87.47
US$110.22
+26.0%
11.0%US$125.00US$85.00n/a9
Nov ’25US$71.48
US$109.80
+53.6%
12.0%US$125.00US$85.00n/a10
Oct ’25US$79.00
US$109.80
+39.0%
12.0%US$125.00US$85.00n/a10
Sep ’25US$75.58
US$112.14
+48.4%
10.9%US$125.00US$85.00n/a7
Aug ’25US$90.13
US$113.29
+25.7%
8.5%US$125.00US$94.00n/a7
Jul ’25US$82.73
US$113.29
+36.9%
8.5%US$125.00US$94.00n/a7
Jun ’25US$84.08
US$113.50
+35.0%
9.1%US$125.00US$94.00n/a6
May ’25US$92.13
US$104.86
+13.8%
11.0%US$120.00US$88.00n/a7
Apr ’25US$84.79
US$107.17
+26.4%
10.2%US$120.00US$88.00n/a6
Mar ’25US$74.16
US$106.17
+43.2%
8.5%US$115.00US$90.00n/a6
Feb ’25US$78.00
US$107.00
+37.2%
8.1%US$115.00US$90.00US$69.056
Jan ’25US$85.51
US$107.00
+25.1%
8.1%US$115.00US$90.00US$78.086
Dec ’24US$84.26
US$107.83
+28.0%
6.6%US$115.00US$95.00US$87.476
Nov ’24US$86.39
US$109.17
+26.4%
7.0%US$115.00US$94.00US$71.486
Oct ’24US$89.58
US$108.50
+21.1%
8.3%US$115.00US$90.00US$79.006
Sep ’24US$90.24
US$108.50
+20.2%
8.3%US$115.00US$90.00US$75.586
Aug ’24US$92.26
US$106.83
+15.8%
8.0%US$115.00US$90.00US$90.136
Jul ’24US$85.14
US$106.83
+25.5%
8.0%US$115.00US$90.00US$82.736
Jun ’24US$86.57
US$106.83
+23.4%
8.0%US$115.00US$90.00US$84.086
May ’24US$82.83
US$100.14
+20.9%
8.5%US$115.00US$88.00US$92.137
Apr ’24US$82.75
US$100.86
+21.9%
7.7%US$115.00US$88.00US$84.797
Mar ’24US$77.22
US$100.86
+30.6%
7.7%US$115.00US$88.00US$74.167
Feb ’24US$84.32
US$96.43
+14.4%
8.7%US$110.00US$84.00US$78.007
Analyst Price Target
Consensus Narrative from 10 Analysts
US$96.80
Fair Value
38.7% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 00:00
End of Day Share Price 2025/02/07 00:00
Earnings2024/12/28
Annual Earnings2024/03/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Haemonetics Corporation is covered by 29 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel OwczarskiAvondale Partners
Ishan MajumdarBaptista Research
Gary PrestopinoBarrington Research Associates, Inc.